临时心室辅助装置的结果:一家儿科机构25年的经验
该回顾性单中心研究分析了1996年至2021年间108例患者植入126台临时心室辅助装置的114次住院结局。85%的住院达到主要终点(恢复、过渡到另一种装置或直接移植),15%在支持期间死亡。研究提示临时心室辅助装置在儿童中可行且结局良好。
要点
- 114次临时心室辅助装置住院中,85%达到主要终点,15%在支持期间死亡。
- 主要终点包括过渡到恢复(55次)、过渡到另一种装置(31次)和直接过渡到移植(11次)。
- 导管轴流泵与体外离心泵的6个月生存率分别为84%和67%(P = .08)。
核心结论
- 本研究提示临时心室辅助装置支持在儿童中可行,且结局良好。
研究设计与样本
- 回顾性单中心研究,回顾1996年至2021年间所有连续接受临时心室辅助装置的患者,以「encounters」(临时心室辅助装置住院,不论使用装置数量)为基础进行结局分析。
- 共108例患者植入126台临时心室辅助装置,形成114次住院。
主要发现
- 114次住院中,70次(61%)使用体外离心泵,44次(39%)使用导管轴流泵。
- 临时心室辅助装置植入时中位年龄为10.1岁(范围1天至42.8岁),中位体重为33.6 kg(范围2.5-128 kg)。
- 心脏功能障碍病因包括心肌病(34例,30%)、心脏移植移植物功能障碍(29例,25%)、先天性心脏病(23例,20%;其中9例单心室)、心肌炎(22例,19%)和其他(6例,5%)。
- Interagency Registry for Mechanically Assisted Circulatory Support分级为1级75例(66%),2级39例(34%)。
- 支持构型为左心室辅助装置104例(包括9例体循环心室辅助装置)、右心室辅助装置5例和双心室辅助装置5例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are scarce data describing outcomes of pediatric temporary ventricular assist device support. METHODS: A retrospective single-center study was conducted to review clinical outcomes of all consecutive patients with temporary ventricular assist device between 1996 and 2021. Given the complex clinical course in some patients requiring multiple temporary ventricular assist device runs, outcome analysis was based on "encounters" (hospitalizations with temporary ventricular assist device, regardless of the number of devices used). RESULTS: In total, 126 temporary ventricular assist devices were implanted in 108 patients, resulting in a total of 114 encounters: 70 (61%) extracorporeal centrifugal pumps and 44 (39%) catheter-based axial pumps. The median (range) age and weight at temporary ventricular assist device implant were 10.1 years (1 day to 42.8 years) and 33.6 (2.5-128) kg, respectively. Underlying etiologies of cardiac dysfunction were cardiomyopathy (34, 30%), cardiac transplant graft dysfunction (29, 25%), congenital heart disease (23, 20%; 9 single ventricle), myocarditis (22, 19%), and other (6, 5%). Interagency Registry for Mechanically Assisted Circulatory Support Profile was 1 in 75 (66%) and 2 in 39 (34%). Support configuration was left ventricular assist device (104, including 9 systemic ventricular assist devices), right ventricular assist device (5), and biventricular assist device (5). The median (range) support duration was 6 (1-61) days. Overall, 97 (85%) encounters reached a positive primary end point: bridge-to-recovery (55), bridge-to-bridge (31), and bridge-to-transplant directly with temporary ventricular assist device (11). Seventeen (15%) encounters resulted in death during temporary ventricular assist device support: multiorgan failure (12), stroke (4), and cardiac arrest (1). The 6-month survivals with catheter-based axial pumps and extracorporeal centrifugal pumps were 84% (95% confidence interval, 74-96) and 67% (95% confidence interval, 57-79), respectively (P = .08). The 1- and 5-year survivals of 82 hospital survivors were 90% and 84%, respectively. CONCLUSIONS: This study suggests temporary ventricular assist device support is feasible in children with favorable outcomes.
引用
- Cho J, Fuentes-Baldemar AA, Tunuguntla HP, et al. Outcomes of temporary ventricular assist device: A pediatric institutional experience over 25 years. J Thorac Cardiovasc Surg. 2022. PMID: 36494210. doi:10.1016/j.jtcvs.2022.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。